Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics

Current Rheumatology Reports

Volumn 10, Issue 5, 2008, Pages 356-363

  Appel, Heiner ^a   Sieper, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; BONE EROSION; HISTOPATHOLOGY; HUMAN; INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOBLAST; PATHOLOGY; REVIEW; RHEUMATOID ARTHRITIS; SACROILIAC JOINT; SACROILIITIS; SPINAL CORD ATROPHY; SPONDYLOARTHROPATHY; SYNDESMOPHYTE; ZYGAPOPHYSEAL JOINT; ANKYLOSING SPONDYLITIS; BONE DEVELOPMENT; DRUG ANTAGONISM; DRUG EFFECT; EARLY DIAGNOSIS; FEMALE; MALE; PATHOPHYSIOLOGY; RADIOGRAPHY; SPINE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; EARLY DIAGNOSIS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; OSTEOGENESIS; SACROILIAC JOINT; SPINE; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 55949088776     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0058-x     Document Type: Review

References (69)

1. Sieper J, Rudwaleit M, Khan MA, Braun J: Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol 2006, 20:401-417.
2. Braun J, Sieper J: Ankylosing spondylitis. Lancet 2007, 369:1379-1390.
3. Rudwaleit M, Metter A, Listing J, et al.: Inflammatory back pain in ankylosing spondylitis: A reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006, 54:569-578.
4. van der Linden SM, Valkenburg HA, de Jongh BM, Cats A: The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984, 27:241-249.
5. Rudwaleit M, Khan MA, Sieper J: The challenge of diagnosis and classification in early ankylosing spondylitis: Do we need new criteria? Arthritis Rheum 2005, 52:1000-1008.
6. Feldtkeller E, Khan MA, van der Heijde D, et al.: Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003, 23:61-66.
7. Brandt HC, Spiller I, Song IH, et al.: Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis 2007, 66:1479-1484.
8. Song IH, Poddubnyy DA, Rudwaleit M, Sieper J: Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 2008, 58:929-938.
9. Braun J, Brandt J, Listing J, et al.: Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 2002, 359:1187-1193.
10. Davis JC Jr, Van Der Heijde D, Braun J, et al.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum 2003, 48:3230-3236.
11. van der Heijde D, Kivitz A, Schiff MH, et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2006, 54:2136-2146.
12. Braun J, Landewe R, Hermann KG, et al.: Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006, 54:1646-1652.
13. Calin A, Mackay K, Santos H, Brophy S: A new dimension to outcome: application of the Bath Ankylosing Spondylitis Radiology Index. J Rheumatol 1999, 26:988-992.
14. Creemers MC, Franssen MJ, van't Hof MA, et al.: Assessment of outcome in ankylosing spondylitis: An extended radiographic scoring system. Ann Rheum Dis 2005, 64:127-129.
15. van der Heijde D, Landewé R, van der Linden S: How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured? Arthritis Rheum 2005, 52:1979-1985.
16. Braun J, Sieper J, Bollow M: Imaging of sacroiliitis. Clin Rheumatol 2000, 19:51-57.
17. Hermann KG, Althoff CE, Schneider U, et al.: Spinal changes in patients with spondyloarthritis: Comparison of MR imaging and radiographic appearances. Radiographics 2005, 25:559-569.
18. Maksymowych WP, Inman RD, Salonen D, et al.: Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 2005, 53:703-709.
19. Haibel H, Rudwaleit M, Brandt HC, et al.: Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006, 54:678-681.
20. Maksymowych WP, Dhillon SS, Park R, et al.: Validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging spinal inflammation index: Is it necessary to score the entire spine? Arthritis Rheum 2007, 57:501-507.
21. Weber U, Pfirrmann CW, Kissling RO, et al.: Whole body MR imaging in ankylosing spondylitis: A descriptive pilot study in patients with suspected early and active confirmed ankylosing spondylitis. BMC Musculoskelet Disord 2007, 8:20.
22. Althoff CE, Appel H, Rudwaleit M, et al.: Whole-body MRI as a new screening tool for detecting axial and peripheral manifestations of spondyloarthritis. Ann Rheum Dis 2007, 66:983-985.
23. Appel H, Hermann KG, Althoff CE, et al.: Whole-body magnetic resonance imaging evaluation of widespread inflammatory lesions in a patient with ankylosing spondylitis before and after 1 year of treatment with infliximab. J Rheumatol 2007, 34:2497-2498.
24. Weber U, Kissling RO, Holder J: Advances in musculoskeletal imaging and their clinical utility in the early diagnosis of spondyloarthritis. Curr Rheumatol Rep 2007, 9:353-360.
25. Weber U, Pfirrmann CWA, Kissling RO, et al.: Early spondyloarthritis in HLA-B27 positive monozygotic twin pair: A highly concordant onset, sites of involvement, and disease course. J Rheumatol 2008, 35:1464-1466.
26. Poole AR: The histopathology of ankylosiAg spondylitis: are there unifying hypotheses? Am J Med Sci 1998, 316:228-233.
27. Maksymowych WP: Ankylosing spondylitis - at the interface of bone and cartilage. J Rheumatol 2000, 27:2295-2301.
28. McGonagle D, Gibbon W, Emery P: Classification of inflammatory arthritis by enthesitis. Lancet 1998, 352:1137-1140.
29. Ball J: Pathology and pathogenesis. In: Ankylosing spondylitis. Edited by Moll JM. Edinburgh: Churchill Livingstone; 1980:96-112.
30. Cruickshank B: Lesions of cartilaginous joints in ankylosing spondylitis. J Pathol Bacteriol 1956, 71:73-84.
31. Bywaters EGL, Olsen E: A case of early ankylosing spondylitis with fatal secondary amyloidosis: Demonstrated at the Royal Postgraduate Medical School. BMJ 1968, 2:412-416.
32. Francois RJ, Gardner DL, Degrave EJ, Bywaters EG: Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum 2000, 43:2011-2024.
33. Braun J, Bollow M, Neure L, et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995, 38:499-505.
34. Savill DL: The manubrio-sternal joint in ankylosing spondylitis. J Bone Joint Surg Br 1951, 33:56-64.
35. Appel H, Kuhne M, Spiekermann S, et al.: Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: Evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum 2006, 54:1805-1813.
36. Braun J, Bollow M, Eggens U, et al.: Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994, 37:1039-1045.
37. Bollow M, Fischer T, Reisshauer H, et al.: Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis - cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000, 59:135-140.
38. Golder W, Karberg K, Sieper J: Fluoroscopy-guided application of corticosteroids for local control of manubriosternal joint pain in patients with spondyloarthropathies. Clin Rheumatol 2004, 23:481-484.
39. McGonagle D, Gibbon W, O'Connor P, et al.: Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 1998, 41:694-700.
40. Lambert RG, Dhillon SS, Jhangri GS, et al.: High prevalence of symptomatic enthesopathy of the shoulder in ankylosing spondylitis: deltoid origin involvement constitutes a hallmark of disease. Arthritis Rheum 2004, 51:681-690.
41. Appel H, Kuhne M, Spiekermann S, et al.: Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006, 54:2845-2851.
42. Appel H, Loddenkemper C, Grozdanovic Z, et al.: Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 2006, 8:R143.
43. Brandt J, Haibel H, Cornely D, et al.: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000, 43:1346-1352.
44. Appel H, Loddenkemper C, Heydrich R, et al.: Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with anyklosing spondylitis reveal repair functions similar to osteoarthritis. Ann Rheum Dis 2008, 67(Suppl II):59.
45. de Vlam K, Lories RJ, Luyten FP: Mechanisms of pathologic new bone formation. Curr Rheumatol Rep 2006, 8:332-337.
46. Lories RJ, Derese I, de Bari C, Luyten FP: Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007, 56:489-497.
47. Ball J: Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis 1971, 30:213-223.
48. Zwerina J, Tuerk B, Redlich K, et al.: Imbalance of local bone metabolism in inflammatory arthritis and its reversal upon tumor necrosis factor blockade: Direct analysis of bone turnover in murine arthritis. Arthritis Res Ther 2006, 8:R22.
49. Walsh NC, Manning CA, Boch JA, et al.: Wnt signalling antagonists are candidates for the suppression of osteoblast differentiation in inflammatory arthritis. Arthritis Rheum 2006, 54(Suppl):S511.
50. Diarra D, Stolina M, Polzer K, et al.: Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163.
51. Lacey DL, Timms E, Tan HL, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
52. Sieper J, Appel H, Braun J, Rudwaleit M: Critical appraisal of assessment of structural damage in ankylosing spondylitis: Implications for treatment outcomes. Arthritis Rheum 2008, 58:649-656.
53. Maksymowych WP, Chiowchanwisawakit P, Clare T, Lambert RG: Inflammatory lesions of the spine on MRI predict the development of new syndesmophytes in ankylosing spondylitis: Evidence for coupling between inflammation and new bone formation. Ann Rheum Dis 2008, 67(Suppl II):130.
54. Baraliakos X, Listing J, Rudwaleit M, et al.: Evidence for a link between inflammation and new bone formation in ankylosing spondylitis - a detailed analysis. Ann Rheum Dis 2008, 67(Suppl II):130.
55. Van der Heijde D, Landewe R, Baraliakos X, et al.: MRI inflammation of the vertebral unit (VU) only marginally contributes to new syndesmophyte formation in that unit: A multi-level analysis. Ann Rheum Dis 2008, 67(Suppl II):130.
56. Schett G, Landewé R, van der Heijde D: Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: What is reality and what is fiction? Ann Rheum Dis 2007, 66:709-711.
57. Rudwaleit M, Schwarzlose S, Hilgert ES, et al.: Magnetic resonance imaging (MRI) in predicting a major clinical response to anti-TNF-treatment in ankylosing spondylitis. Ann Rheum Dis 2007, (Nov 15 Epub ahead of print).
58. Haibel H, Rudwaleit M, Listing J, et al.: Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelveweek randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008, 58:1981-1991.
59. Barkham N, Keen HI, Coates LC, et al.: A randomized controlled trial of infliximab shows clinical and MRI efficacy in HLA-B27 positive very early ankylosing spondylitis. Ann Rheum Dis 2008, 67(Suppl II):382.
60. Sieper J, Baraliakos X, Listing J, et al.: Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 2005, 44:1525-1530.
61. Braun J, Baraliakos X, Listing J, et al.: Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: Evidence for different types of response. Ann Rheum Dis 2008, 67:340-345.
62. Heiberg MS, Koldingsnes W, Mikkelsen K, et al.: The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008, 59:234-240.
63. van der Heijde D, Landewé R, Einstein S, et al.: Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008, 58:1324-1331.
64. van der Heijde D, Landewe R, Deoadar A, et al.: Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment not inhibited with infliximab. Ann Rheum Dis 2007, 66(Suppl II):85-86; OP0111.
65. Braun J, Han C, Kellner H, et al.: Infliximab improves spinal mobility in patients with ankylosing spondylitis: Two year findings from the ASSERT clinical trial. Ann Rheum Dis 2007, 66(Suppl II):390.
66. Braun J, Sieper J: What is the most important outcome parameter in ankylosing spondylitis? Rheumatology 2008 (in press).
67. Lories RJ, Derese I, Luyten FP: Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005, 115:1571-1579.
68. Lories RJ, Daans M, Derese I, et al.: Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis Rheum 2006, 54:1736-1746.
69. Wanders A, Heijde D, Landewé R, et al.: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. Arthritis Rheum 2005, 52:1756-1765.